Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients

Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients

BACKGROUND: Multiple myeloma (MM) represents the second most common hematologic malignancy (15%). Induction with bortezomib, cyclophosphamide, and dexamthasone VCd (d: low dose dexamthasone) regimen is widely used due to its high effectiveness, low toxicity and good tolerability, particularly with r...

Full description

Bibliographic Details
Main Authors: Ahmed Kotb Abdrabou, Fahad Al Sharif, Riad El Fakih, Hazaa Al Zahrani, Ruah Al Yamany, Mostafa Saleh, Saud Alhayli, Zakia Al Somali, Ahmad Alotaibi, AlFadel AlShaibani, Farah Deeba, Maryam Asif, Syed Ahmed Osman Ali Ahmed, Feras Al Fraih, Marwan Shaheen, Ali Alahmari, Walid Rasheed, Naeem Arshad Chaudhri, Fahad Al Mohareb, Mahmoud Aljurf, Amr Hanbali
Format: Article
Language:English
Published: King Faisal Specialist Hospital and Research Centre 2024-03-01
Series:Annals of Saudi Medicine
Online Access:http://www.annsaudimed.net/doi/10.5144/0256-4947.2024.93

Internet

http://www.annsaudimed.net/doi/10.5144/0256-4947.2024.93

Similar Items